Product Dossier

CEFEPIME KABI

Product Dossier for CEFEPIME KABI (cefepime, Fresenius Kabi). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.

Sponsor: Fresenius Kabi
Active ingredient: cefepime
Therapeutic area: Infectious Disease
Related brand: Cefepime-AFT
Same area: RETROVIR
Same area: Savacol Antiseptic Mouth & Throat Rinse

I appreciate the task, but

I must inform you that the provided source document contains only ARTG registration details for CEFEPIME KABI (strength, formulation, and registration dates). It does not contain sufficient information to populate most of the required sections for a comprehensive Brand Dossier.

To create a complete Brand Dossier following your specifications, I would require source documents containing: — Clinical indications and approved uses — Dosing recommendations and regimens — Safety warnings and adverse effects — Contraindications — PBS listing details (item numbers, restriction types, pricing) — Regulatory history (PBAC outcomes, AusPAR information, Black Triangle status)

With only the ARTG registration information available, I can only reliably populate the following:

What it is

CEFEPIME KABI is cefepime hydrochloride, supplied as a powder for injection in 1 g and 2 g vial strengths.

Regulatory history

CEFEPIME KABI was first registered on the ARTG on 7 September 2015. ---

To complete this Brand Dossier with the remaining sections (Approved indications, Dosing overview, Key safety warnings, Contraindications, and PBS listing), please provide source documents containing product information, clinical trial data, PBAC submissions, or product information leaflets.